Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.